The addition of alprostadil [lipo-prostaglandin E1] to conventional therapy improves exercise intolerance and lowers pulmonary BP in patients with pulmonary arterial hypertension (PAH)

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1504, 2005-01, pp. : 9-9

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

PLGA Microparticles Encapsulating Prostaglandin E1-Hydroxypropyl-β-cyclodextrin (PGE1-HPβCD) Complex for the Treatment of Pulmonary Arterial Hypertension (PAH)

By Gupta Vivek   Davis Marauo   Hope-Weeks Louisa   Ahsan Fakhrul  

Pharmaceutical Research, Vol. 28, Iss. 7, 2011-07 ,pp. : 1733-1749

Springer Publishing Company

Access to resources Recommend Favorite

Inhaled treprostinil is an effective, well-tolerated add-on therapy for patients with pulmonary arterial hypertension (PAH) treated with bosentan

By  

Inpharma, Vol. 1, Iss. 1561, 2006-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Medical therapy for pulmonary arterial hypertension

By Driscoll James A   Chakinala Murali M  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 1, 2008-01 ,pp. : 65-81

Informa Healthcare

Access to resources Recommend Favorite

Sitaxsentan sodium appears to be more cost effective than bosentan in treating patients with pulmonary arterial hypertension (PAH)

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 508, 2006-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Bosentan improves exercise capacity in pulmonary hypertension

By  

Inpharma, Vol. 1, Iss. 1309, 2001-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite